NeuWire Medical gets FDA go-ahead for pivotal vagus nerve stimulation stroke trial
The STROKE-REWIRE study will test a wireless, battery-free implant that pairs vagus nerve stimulation with arm rehabilitation in up to 135 people with chronic stroke.
NeuWire Medical said on October 5 that the FDA approved an Investigational Device Exemption for STROKE-REWIRE, a pivotal trial of its ReWire vagus nerve stimulation system for arm weakness after ischemic stroke. The implant is small, wireless and battery-free. It uses closed-loop sensing to deliver stimulation when a patient makes a successful rehabilitation movement. The randomized, sham-controlled study will enroll up to 135 people with chronic stroke at up to 12 US sites. Its main measure is the change in upper-limb Fugl-Meyer score after 18 clinic sessions, with two years of follow-up that includes home use. The company expects to start the study in the first half of 2027.
The technology comes out of research at UT Dallas’s Texas Biomedical Device Center. An IDE lets the study go ahead but says nothing about whether the device is safe or effective.
Learn more: Neuroplasticity · Closed-loop system